References
- 1. World Health Organization. WHO model list of essential medicines, http://www.who.int/medicines/publications/essentialmedicines/en/index.html (2005).
- 2. U.S. Food and Drug Administration. Methadone Hydrolcholoride. FDA alert [11/2006]: death, narcotic overdose, and serious cardiac arrhythmias. [updated 2008 August 23; cited 2006 Nov 29] Available from: http://www.fda.gov/cder/drug/advisory/methadone.htm
- 3. Cruciani RA. Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage. 2008 Nov;36(5):545-52.
- 4. Kristensen, K, Christensen, C, The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56, L45–L50 (1995).
- 5. Gorman, A.L., Elliott.The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-Daspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223, 5–8 (1997).
- 6. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19:565–76.
- 7. Eap, C.B., Buclin, T. & Baumann, P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet.41, 1153–1193 (2002).
- 8. Gerber, J.G., Rhodes, R.J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36–44 (2004).
- 9. Crettol, S. et al. Methadone enantiomer plasma levels CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593–604 (2005).
- 10. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19:4–16.
- 11. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD002208
- 12. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
- 13. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7:353–70.
- 14. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. December 1997 [CPMP/986/96].
- 15. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
- 16. Sanguinetti, M.C, Jiang, C, Curran, M.E. & Keating, M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299–307 (1995).
- 17. Katchman, A.N. et al. Influence of opioid agonists on cardiac humanether-a-go-go-related gene K+ currents. J. Pharmacol. Exp. Ther. 303,688–694 (2002). xxx. Kornick, C.A. et al. QTc interval prolongation associated with intravenous methadone. Pain 105, 499–506 (2003).
- 18. Kornick, C.A. et al. QTc interval prolongation associated with intravenous methadone. Pain 105, 499–506 (2003).
- 19. Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, Scherbaum N. Levo-alphaacetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial. Eur J Med Res. 2009 Jan 28;14(1):7-12.
- 20. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007 Dec 10;167(22):2469-75.
- 21. Krantz M. Heterogeneous Impact of Methadone on the QTc Interval: What Are the Practical Implications? J Addict Dis. 2008;27(4):5-9.
- 22. Krantz M, Lowery C, Martell B, Gourevitch M and Arnsten J. Effects of Methadone on QT-Interval Dispersion. Pharmacotherapy 2005;25(11):1523–1529.
- 23. Martell B, MD, Arnsten J, Krantz M, and Gourevitch M. Impact of Methadone Treatment on Cardiac Repolarization and Conduction in Opioid Users. Am J Cardiol 2005;95:915–918
- 24. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res. 2005;11(1):44-9.
- 25. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev. 2011 Jul;30(4):388-96.
- 26. MHRA and Commission on Human Medicines. Risk of QT interval prolongation with methadone. 2006 May. Report No.: 31.
- 27. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011 Aug;25(4):503-10.
- 28. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009 Jun;104(6):993-9.
- 29. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment treatment (MMT) patients: a cross-sectional study. Addiction. 2007 Feb;102(2):289-300.
- 30. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, Abriel H. Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers. Clin Pharmacol Ther. 2007 May; 81(5):719-28.
- 31. Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med. 2007 Apr;32(3):275-8. Epub 2007 Feb 2.
- 32. Lamont P, Hunt SC. A twist on torsade: a prolonged QT interval on methadone. J Gen Intern Med. 2006 Nov;21(11):C9-C12.
- 33. Sanchez Hernandez AM, Atienza Fernandez F, Arenal Maiz A, Gonzalez Torrecilla E, Puchol Calderon A, Almendral Garrote J. Torsades de pointes during methadone treatment. Rev Esp Cardiol. 2005 Oct;58(10):1230-2.
- 34. U.S. Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland; 2005.
- 35. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004 Mar 4;350(10):1013-22.
- 36. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend. 2010 Dec 1;112(3):216-9. doi: 10.1016/j.drugalcdep.2010.06.015. Epub 2010 Aug 10.